Volume 4.09 | Mar 12

Hematopoiesis News 4.09 March 12, 2013
Hematopoiesis News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
An Epigenetic Component of Hematopoietic Stem Cell Aging Amenable to Reprogramming into a Young State
The authors hypothesized that hematopoietic stem cell aging is driven by the acquisition of permanent genetic mutations. To examine this issue at a functional level in vivo, they applied induced pluripotent stem (iPS) cell reprogramming of aged hematopoietic progenitors and allowed the resulting aged-derived iPS cells to reform hematopoiesis via blastocyst complementation. [Blood] Abstract

STEMvision(TM) Instrument
PUBLICATIONS (Ranked by impact factor of the journal)


Hematopoietic Progenitor Kinase 1 (HPK1) Is Required for Lymphocyte Function-Associated Antigen 1-Mediated Neutrophil Recruitment during the Acute Inflammatory Response
Investigators showed that mammalian actin-binding protein 1 constitutively co-immunoprecipitated with hematopoietic progenitor kinase 1 in neutrophil-like differentiated HL-60 cells. [Blood] Abstract

The Eukaryotic Translation Initiation Factor eIF4E Is a Direct Transcriptional Target of NF-κB and Is Aberrantly Regulated in Acute Myeloid Leukemia
In primary acute myeloid leukemia (AML) specimens, generally scientists observed that substantially more NF-κB complexes associate with eIF4E promoter elements in M4 and M5 AML specimens examined than in other subtypes or unstimulated normal primary hematopoietic cells. [Leukemia] Abstract

Aberrant Mer Receptor Tyrosine Kinase Expression Contributes to Leukemogenesis in Acute Myeloid Leukemia
Researchers found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric and adult primary acute myeloid leukemia patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse. [Oncogene] Full Article | Press Release

Potential Contribution of a Novel Tax Epitope-Specific CD4+ T Cells to Graft-versus-Tax Effect in Adult T Cell Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation
Scientists showed that Tax-specific CD4+ as well as CD8+ T cell responses were induced in some adult T cell leukemia/lymphoma patients following allogeneic hematopoietic stem cell transplantation. [J Immunol] Abstract

A Natural-Like Synthetic Small Molecule Impairs Bcr-Abl Signaling Cascades and Induces Megakaryocyte Differentiation in Erythroleukemia Cells
Some newly-shaped small molecules showed antiproliferative, pro-apoptotic and differentiating activity in leukemia cell lines. To investigate more in depth the mechanisms of action of these molecules, the protein expression profiles of K562 cells treated with or without the compounds IND_S1, MEL_T1, IND_S7 and MEL_S3 were analyzed using two-dimensional gel electrophoresis coupled with mass spectrometry. [PLoS One] Full Article

Combining Dasatinib with Dexamethasone Longterm Leads to Maintenance of Anti-Viral and Anti-Leukemia Specific Cytotoxic T Cell Responses In Vitro
The authors evaluated combination effects of dasatinib and dexamethasone on CD3+ and virus-specific CD8+ T cells directly ex vivo as well as on antigen-specific leukemia- and allo-reactive CD8+ T cell clones. [Exp Hematol] Abstract

Mutation of the NPM1 Gene Contributes to the Development of Donor Cell-Derived Acute Myeloid Leukemia after Unrelated Cord Blood Transplantation for Acute Lymphoblastic Leukemia
Researchers report a new case of donor cell leukemia after unrelated cord blood transplantation in a 44-year-old woman diagnosed as having acute lymphoblastic leukemia with t(1;19) that developed acute myeloid leukemia with normal karyotype and nucleophosmin (NPM1) mutation in donor cells. [Hum Pathol] Abstract


Two Dosing Regimens of Tosedostat in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (OPAL): A Randomized Open-Label Phase II Study
Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous Phase I/II study in elderly patients with relapsed or refractory acute myeloid leukemia. Researchers aimed to compare two dosing regimens of tosedostat. [Lancet Oncol] Abstract

Rates of Peripheral Arterial Occlusive Disease in Patients with Chronic Myeloid Leukemia in the Chronic Phase Treated with Imatinib, Nilotinib, or Non-Tyrosine Kinase Therapy: A Retrospective Cohort Analysis
The risk of developing peripheral arterial occlusive disease on tyrosine kinase inhibitor (TKI) therapy is unknown and causality has not been established. Patients with chronic phase chronic myeloid leukemia from three randomized Phase III studies were divided into three cohorts: no TKI, nilotinib, and imatinib. [Leukemia] Abstract

New StemSpan(TM) SFEM II - for optimal CD34+ cell expansion of bone marrow and cord blood cells

Allogeneic Hematopoietic Cell Transplantation from Alternative Sources for Adult Philadelphia Chromosome-Negative ALL: What Should We Choose When No HLA-Matched Related Donor Is Available?
The best outcome for patients with Ph chromosome-negative ALL can be obtained by HLA-matched related donor (mRD) allogeneic hematopoietic cell transplantation in first CR. However, only 30% of patients have a mRD. Three alternative sources, unrelated donor, cord blood, and haploidentical related donor, are available. [Bone Marrow Transplant] Abstract

Enter Our Contest  
Hematopoiesis News is giving away a free registration for the 11th Annual International Cord Blood Symposium in San Francisco! A Forum for Education, Science and Medical Professionals. Click here to enter.

NeoStem Reports Second Data Safety Monitoring Board Review: Continue with PreSERVE AMI Phase II Trial as Planned
NeoStem, Inc. announced that it received approval to continue the PreSERVE AMI Phase II clinical trial following its second interim data and safety review by the Data Safety Monitoring Board. The PreSERVE trial of AMR-001 is a Phase II, randomized, placebo controlled, double-blind study designed to treat 160 patients and is approved by the FDA to enroll up to 180 patients. AMR-001 is being evaluated for the prevention of major adverse cardiac events following acute myocardial infarction. [NeoStem, Inc.] Press Release

Saneron and USF Patent Method for Umbilical Cord Blood Cell Use
Researchers at Saneron CCEL Therapeutics, Inc. and the University of South Florida (USF) have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as Parkinson’s disease, Huntington’s disease, multiple sclerosis, Alzheimer’s disease as well as brain and spinal cord injury. [Newswise, Inc.] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 11th Annual International Cord Blood Symposium
June 6-8, 2013
San Francisco, United States

Visit our events page to see a complete list of events in the hematopoietic community.


Postdoctoral Position – Hematopoietic and Malignant Stem Cells (Istanbul University)

Postdoctoral Position – Stem Cell Biology (Washington University of Medicine)

Postdoctoral Position – Stem Cell Research (University of Washington)

Postdoctoral Position – Hematopoietic Stem Cells and Stem Cell Aging (Cincinnati Children’s Hospital Research Foundation)

Lecturer or Reader – Associate Professor (University of Reading)

Research Assistant – Stem Cell & Leukemia Epigenetics (King’s College London)

Postdoctoral Position – Bioinformatics and Stem Cell Biology (University of Texas at Houston)

Postdoctoral Position – Stem Cells and Cancer (Tsinghua University)

Cord Blood Laboratory Manager (Puget Sound Blood Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada